Current Report Filing (8-k)
June 10 2022 - 4:31PM
Edgar (US Regulatory)
0001649904
false
0001649904
2022-06-08
2022-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 8, 2022
RHYTHM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware |
|
001-38223 |
|
46-2159271 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
222 Berkeley Street
12th Floor
Boston, MA 02116
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (857) 264-4280
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
RYTM |
The Nasdaq Stock Market LLC (Nasdaq Global Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07. Submission of Matters to a Vote of Security Holders.
On
June 8, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 41,187,133
shares of common stock were present online or represented by proxy at the meeting, representing approximately 81.73% percent of the Company’s
outstanding common stock as of the April 13, 2022 record date. The following are the voting results for the proposals considered and voted
upon at the meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange
Commission on April 28, 2022.
Item
1 — Election of two Class II Directors to serve until the 2025 Annual Meeting of Stockholders, and until their respective
successors have been duly elected and qualified.
NOMINEE |
|
Votes FOR |
|
|
Votes WITHHELD |
|
|
Broker Non-Votes |
|
Jennifer Good |
|
25,735,447 |
|
|
12,136,923 |
|
|
3,314,763 |
|
Edward T. Mathers |
|
21,035,181 |
|
|
16,837,189 |
|
|
3,314,763 |
|
Item
2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm
for the year ending December 31, 2022.
Votes FOR |
|
Votes AGAINST |
|
|
Votes ABSTAINED |
|
|
Broker Non-Votes |
|
41,171,563 |
|
13,110 |
|
|
2,460 |
|
|
0 |
|
Item 3 — Approval, on an advisory (non-binding)
basis, of the compensation of the Company’s named executive officers.
Votes FOR |
|
Votes AGAINST |
|
Votes ABSTAINED |
|
Broker Non-Votes |
29,672,176 |
|
7,066,219 |
|
1,133,975 |
|
|
3,314,763 |
Based
on the foregoing votes, Jennifer Good and Edward T. Mathers were elected as Class II Directors, and
Items 2 and 3 were approved.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RHYTHM PHARMACEUTICALS, INC. |
|
|
|
Date: June 10, 2022 |
By: |
/s/ Hunter Smith |
|
|
Hunter Smith |
|
|
Chief Financial Officer |
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Oct 2023 to Oct 2024